Heinzelmann Elisa, Piraino Francesco, Costa Mariana, Roch Aline, Norkin Maxim, Garnier Virginie, Homicsko Krisztian, Brandenberg Nathalie
Doppl SA, Lausanne, Switzerland.
Department of Oncology, CHUV, Lausanne, Switzerland.
Curr Res Toxicol. 2024 Oct 2;7:100197. doi: 10.1016/j.crtox.2024.100197. eCollection 2024.
Recent advancements in stem cell technology have led to the development of organoids - three-dimensional (3D) cell cultures that closely mimic the structural and functional characteristics of human organs. These organoids represent a significant improvement over traditional two-dimensional (2D) cell cultures by preserving native tissue architecture and cellular interactions critical for physiological relevance. This review provides a comprehensive comparison between two main types of organoids: induced Pluripotent Stem Cell (iPSC)-derived and Adult Stem Cell (ASC)-derived (also known as Patient-Derived Organoids, PDOs). iPSC-derived organoids, derived from reprogrammed cells, exhibit remarkable plasticity, and can model a wide range of tissues and developmental stages. They are particularly valuable for studying early human development, genetic disorders, and complex diseases. However, challenges such as prolonged differentiation protocols and variability in maturation levels remain significant hurdles. In contrast, ASC-derived organoids, generated directly from patient tissues, faithfully recapitulate tissue-specific characteristics and disease phenotypes. This fidelity makes them indispensable for personalized medicine applications, including drug screening, disease modeling, and understanding individualized treatment responses. The review highlights the unique advantages and limitations of each organoid type, emphasizing their roles in advancing biomedical research and drug discovery. It addresses key challenges in organoid technology, such as scalability, reproducibility, and the need for standardized culture protocols. Furthermore, it explores recent innovations in scaffold-guided organoid engineering and the integration of organoids with advanced technologies like artificial intelligence and high-throughput screening. The integration of organoids with cutting-edge technologies holds promise for enhancing their utility in modeling complex human diseases and accelerating drug discovery and development. By providing more physiologically relevant models of human organs, organoid technology is poised to revolutionize biomedical research, offering new insights into disease mechanisms and personalized therapeutic strategies.
干细胞技术的最新进展催生了类器官——一种三维(3D)细胞培养物,能紧密模拟人体器官的结构和功能特征。与传统的二维(2D)细胞培养相比,这些类器官有显著改进,保留了对生理相关性至关重要的天然组织结构和细胞间相互作用。本综述全面比较了两种主要类型的类器官:诱导多能干细胞(iPSC)来源的和成人干细胞(ASC)来源的(也称为患者来源类器官,PDO)。iPSC来源的类器官由重编程细胞产生,具有显著的可塑性,可模拟多种组织和发育阶段。它们在研究人类早期发育、遗传疾病和复杂疾病方面特别有价值。然而,诸如延长分化方案和成熟水平的变异性等挑战仍然是重大障碍。相比之下,ASC来源的类器官直接从患者组织产生,忠实地再现组织特异性特征和疾病表型。这种保真度使其在个性化医学应用中不可或缺,包括药物筛选、疾病建模和理解个体化治疗反应。该综述强调了每种类器官类型的独特优势和局限性,强调了它们在推进生物医学研究和药物发现中的作用。它讨论了类器官技术中的关键挑战,如可扩展性、可重复性以及对标准化培养方案的需求。此外,它还探讨了支架引导类器官工程的最新创新以及类器官与人工智能和高通量筛选等先进技术的整合。类器官与前沿技术的整合有望提高它们在模拟复杂人类疾病以及加速药物发现和开发方面的效用。通过提供更具生理相关性的人体器官模型,类器官技术有望彻底改变生物医学研究,为疾病机制和个性化治疗策略提供新的见解。